{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:06:43Z","timestamp":1790770003766,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T00:00:00Z","timestamp":1458086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T00:00:00Z","timestamp":1458086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research grant from Merck Sharp & Dohme Corp."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00280-016-3005-y","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T19:52:20Z","timestamp":1458330740000},"page":"865-873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis"],"prefix":"10.1007","volume":"77","author":[{"given":"Dong-Yeop","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Ho","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,16]]},"reference":[{"issue":"5","key":"3005_CR1","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol Off J Am Soc Clin Oncol 20(5):1288\u20131294","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"3005_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5045\/br.2014.49.1.15","volume":"49","author":"BW Kang","year":"2014","unstructured":"Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, Kim WS, Lee JJ, Lee SR, Park KU, Lee HS, Lee WS, Won JH, Park MR, Kwak JY, Kim MK, Kim HJ, Oh SY, Kang HJ, Suh C (2014) Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the Consortium for Improving Survival of Lymphoma. Blood Res 49(1):15\u201321","journal-title":"Blood Res"},{"issue":"9","key":"3005_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706\u2013714","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 3","key":"3005_CR4","doi-asserted-by":"publisher","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, Group EGW (2014) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii83\u201392","journal-title":"Ann Oncol"},{"issue":"4","key":"3005_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bjh.12046","volume":"159","author":"P McKay","year":"2012","unstructured":"McKay P, Leach M, Jackson R, Cook G, Rule S (2012) Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 159(4):405\u2013426","journal-title":"Br J Haematol"},{"issue":"3","key":"3005_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma G (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+\u00a0autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158(3):355\u2013362","journal-title":"Br J Haematol"},{"issue":"9","key":"3005_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E (2015) Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Br J Cancer 112(9):1575\u20131584","journal-title":"Br J Cancer"},{"issue":"1\u20132","key":"3005_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3109\/10428190009057644","volume":"37","author":"A Josting","year":"2000","unstructured":"Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Sohngen D, Tesch H, Wolf J, Diehl V, Engert A (2000) Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed\/refractory mantle-cell lymphoma. Leuk Lymphoma 37(1\u20132):185\u2013187","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"3005_CR9","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/cncr.23880","volume":"113","author":"M Wang","year":"2008","unstructured":"Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J (2008) Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734\u20132741","journal-title":"Cancer"},{"issue":"9","key":"3005_CR10","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","volume":"99","author":"AK Gopal","year":"2002","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99(9):3158\u20133162","journal-title":"Blood"},{"issue":"9","key":"3005_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kruger","year":"2014","unstructured":"Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Niederwieser D, Dolken G (2014) Allogeneic stem cell transplantation for mantle cell lymphoma\u2013final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO). Ann Hematol 93(9):1587\u20131597","journal-title":"Ann Hematol"},{"issue":"13","key":"3005_CR12","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1182\/blood-2001-12-0269","volume":"100","author":"AM Tsimberidou","year":"2002","unstructured":"Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F (2002) Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100(13):4351\u20134357","journal-title":"Blood"},{"issue":"1","key":"3005_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/1042819031000139765","volume":"45","author":"R Bordonaro","year":"2004","unstructured":"Bordonaro R, Petralia G, Restuccia N, Todaro AM, Serraino D, Giuffrida D, Cordio S, Giannitto-Giorgio C, Salice P, Ursino M, Novello G, Marletta F, Manusia M (2004) Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin\u2019s lymphomas with unfavorable prognostic factors: results of a phase II study. Leuk Lymphoma 45(1):93\u2013100","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3005_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.21151","volume":"104","author":"AM Tsimberidou","year":"2005","unstructured":"Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P (2005) Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104(2):345\u2013353","journal-title":"Cancer"},{"issue":"15","key":"3005_CR15","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol Off J Am Soc Clin Oncol 29(15):2011\u20132019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"3005_CR16","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","volume":"24","author":"N Robert","year":"2006","unstructured":"Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(18):2786\u20132792","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9742","key":"3005_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"issue":"1","key":"3005_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/PPO.0b013e31803c72ba","volume":"13","author":"JM Mehnert","year":"2007","unstructured":"Mehnert JM, Kelly WK (2007) Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 13(1):23\u201329","journal-title":"Cancer J"},{"issue":"12","key":"3005_CR19","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","volume":"13","author":"SS Ramalingam","year":"2007","unstructured":"Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res Off J Am Assoc Cancer Res 13(12):3605\u20133610","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"3005_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-014-3008-5","volume":"146","author":"Y Tu","year":"2014","unstructured":"Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA (2014) A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat 146(1):145\u2013152","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"3005_CR21","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesqui\u00e8res H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E (2015) Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol 2(4):e160\u2013e165","journal-title":"Lancet Haematol"},{"issue":"9","key":"3005_CR22","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","volume":"29","author":"M Kirschbaum","year":"2011","unstructured":"Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 29(9):1198\u20131203","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"3005_CR23","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","volume":"110","author":"N Kawamata","year":"2007","unstructured":"Kawamata N, Chen J, Koeffler HP (2007) Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 110(7):2667\u20132673","journal-title":"Blood"},{"issue":"5","key":"3005_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"3005_CR25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1023\/B:QURE.0000021692.81214.70","volume":"13","author":"YH Yun","year":"2004","unstructured":"Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K (2004) Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 13(4):863\u2013868","journal-title":"Qual Life Res"},{"issue":"6","key":"3005_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00520-004-0632-3","volume":"12","author":"YH Yun","year":"2004","unstructured":"Yun YH, Bae SH, Kang IO, Shin KH, Lee R, Kwon SI, Park YS, Lee ES (2004) Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Support Care Cancer 12(6):441\u2013445","journal-title":"Support Care Cancer"},{"issue":"5","key":"3005_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3005_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310","journal-title":"Control Clin Trials"},{"issue":"4","key":"3005_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346","journal-title":"Control Clin Trials"},{"issue":"28","key":"3005_CR30","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol Off J Am Soc Clini Oncol 23(28):7013\u20137023","journal-title":"J Clin Oncol Off J Am Soc Clini Oncol"},{"issue":"1","key":"3005_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O, Groupe d\u2019Etude des Lymphomes de lA (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood 121(1):48\u201353","journal-title":"Blood"},{"issue":"13","key":"3005_CR32","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hanel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W, German Low Grade Lymphoma Study G (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003\u20134008","journal-title":"Blood"},{"issue":"2","key":"3005_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","volume":"80","author":"U Heider","year":"2008","unstructured":"Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O (2008) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80(2):133\u2013142","journal-title":"Eur J Haematol"},{"issue":"12","key":"3005_CR34","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","volume":"17","author":"S Xargay-Torrent","year":"2011","unstructured":"Xargay-Torrent S, Lopez-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, Roue G, Colomer D (2011) Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res Off J Am Assoc Cancer Res 17(12):3956\u20133968","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"3005_CR35","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3109\/10428194.2011.634043","volume":"53","author":"BC Valdez","year":"2012","unstructured":"Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS (2012) Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma 53(5):973\u2013981","journal-title":"Leuk Lymphoma"},{"issue":"7\u20138","key":"3005_CR36","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.biocel.2007.03.009","volume":"39","author":"M Tsapis","year":"2007","unstructured":"Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P, Gronemeyer H (2007) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 39(7\u20138):1500\u20131509","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"3005_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00432-015-2026-y","volume":"142","author":"K Xue","year":"2016","unstructured":"Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y (2016) Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. J Cancer Res Clin Oncol 142(2):379\u2013387","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"3005_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.leukres.2012.01.027","volume":"36","author":"W Shi","year":"2012","unstructured":"Shi W, Han X, Yao J, Yang J, Shi Y (2012) Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. Leuk Res 36(6):749\u2013755","journal-title":"Leuk Res"},{"issue":"3","key":"3005_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3324\/haematol.2014.117473","volume":"100","author":"R Chen","year":"2015","unstructured":"Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M (2015) A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma. Haematologica 100(3):357\u2013362","journal-title":"Haematologica"},{"issue":"5","key":"3005_CR40","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/bjh.13195","volume":"168","author":"DJ Straus","year":"2015","unstructured":"Straus DJ, Hamlin PA, Matasar MJ, Lia Palomba M, Drullinsky PR, Zelenetz AD, Gerecitano JF, Noy A, Hamilton AM, Elstrom R, Wegner B, Wortman K, Cella D (2015) Phase I\/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. Br J Haematol 168(5):663\u2013670","journal-title":"Br J Haematol"},{"issue":"2","key":"3005_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bjh.12230","volume":"161","author":"LE Budde","year":"2013","unstructured":"Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, Chen TL, Knudsen NL, Roden JE, Kammerer BE, Frayo SL, Warr TA, Boyd TE, Press OW, Gopal AK (2013) A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol 161(2):183\u2013191","journal-title":"Br J Haematol"},{"issue":"4","key":"3005_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","volume":"36","author":"VY Yazbeck","year":"2008","unstructured":"Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A (2008) Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36(4):443\u2013450","journal-title":"Exp Hematol"},{"issue":"13","key":"3005_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.4161\/cbt.8.13.8726","volume":"8","author":"R Rao","year":"2009","unstructured":"Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN (2009) Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther 8(13):1273\u20131280","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"3005_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10495-015-1125-1","volume":"20","author":"K Hagiwara","year":"2015","unstructured":"Hagiwara K, Kunishima S, Iida H, Miyata Y, Naoe T, Nagai H (2015) The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. Apoptosis 20(7):975\u2013985","journal-title":"Apoptosis"},{"issue":"2","key":"3005_CR45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 18(2):317\u2013324","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"3005_CR46","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA (2013) Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol Off J Am Soc Clin Oncol 31(23):2912\u20132919","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"3005_CR47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/bjh.12769","volume":"165","author":"M Furtado","year":"2014","unstructured":"Furtado M, Dyer MJ, Johnson R, Berrow M, Rule S (2014) Ofatumumab monotherapy in relapsed\/refractory mantle cell lymphoma\u2013a phase II trial. Br J Haematol 165(4):575\u2013578","journal-title":"Br J Haematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-016-3005-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3005-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:43:34Z","timestamp":1659059014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-016-3005-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,16]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["3005"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3005-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,16]]},"assertion":[{"value":"24 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Won Seog Kim received a research grant from Merck Sharp & Dohme Corp. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}